Exploring Different Strategies of Assessing the Economic Impact of Multiple Diabetes-Associated Complications and Their Interactions: A Large Claims-Based Study in Germany

PharmacoEconomics
Katharina KähmRolf Holle

Abstract

In the context of an aging population with increasing diabetes prevalence, people are living longer with diabetes, which leads to increased multimorbidity and economic burden. The primary aim was to explore different strategies that address the economic impact of multiple type 2 diabetes-related complications and their interactions. We used a generalized estimating equations approach based on nationwide statutory health insurance data from 316,220 patients with type 2 diabetes (baseline year 2012, 3 years of follow-up). We estimated annual total costs (in 2015 euros) for type 2 diabetes-related complications and, in addition, explored different strategies to assess diabetes-related multimorbidity: number of prevalent complications, co-occurrence of micro- and macrovascular complications, disease-disease interactions of prevalent complications, and interactions between prevalent/incident complications. The increased number of complications was significantly associated with higher total costs. Further assessment of interactions showed that macrovascular complications (e.g., chronic heart failure) and high-cost complications (e.g., end-stage renal disease, amputation) led to significant positive effects of interactions on costs, w...Continue Reading

References

May 22, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN CDC Diabetes Cost-effectiveness Group
Jun 19, 2004·Current Opinion in Nephrology and Hypertension·Donald SilverbergAdrian Iaina
Aug 31, 2006·Health Economics·Alan BrennanRuth Davies
Oct 11, 2007·Diabetes, Obesity & Metabolism·Andrew J KrentzChristopher D Byrne
Dec 8, 2009·European Journal of Epidemiology·Stefan Walter, Henning Tiemeier
Jun 10, 2010·Current Diabetes Reports·Agbor NdipAndrew J M Boulton
Aug 7, 2010·Stroke; a Journal of Cerebral Circulation·Amitava BanerjeePeter M Rothwell
Aug 27, 2010·Diabetes Care·Lawrence A LaveryAndrew J M Boulton
Aug 28, 2010·Health Economics·Borislava MihaylovaSimon G Thompson
Jul 20, 2011·Health and Quality of Life Outcomes·Matthias HungerRolf Holle
Sep 12, 2012·Archives of Ophthalmology·Juan E GrunwaldUNKNOWN CRIC Study Group
Jul 19, 2013·Clinical Epidemiology·Anne Gulbech Ording, Henrik Toft Sørensen
May 2, 2014·Advances in Chronic Kidney Disease·Ragnar Pálsson, Uptal D Patel
Apr 18, 2015·Journal of Diabetes Research·Antonino TuttolomondoAntonio Pinto
Feb 2, 2016·Health Policy·Kristine KreisJan Zeidler
Nov 9, 2016·Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición·Roberto Nuño-SolinísSonia Gaztambide
Mar 2, 2017·Der Internist·E BattegayS Rampini
Apr 8, 2017·PloS One·Duck Jin HwangSe Joon Woo
Feb 25, 2018·Diabetes Care·Christian BommerSebastian Vollmer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aging & Diabetes

This feed focuses on the role of the aging process on developing diabetes.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Aging-Associated Metabolic Disorders

Age is associated with many metabolic disorders including cardiovascular diseases, type 2 diabetes, stroke and heart disease. The mediators in aging process have been suggested to play a part in the cellular processes responsible for these metabolic disorders. Here is the latest research on aging-associated metabolic disorders.